ERBB2 and neoplasm: In the overall population, HER-2 overexpression was found to be a significant predictor of DFS and PFS performing significantly better than “traditional” prognostic factors (sex, tumor size/number/recurrence), on which the currently available (EORTC and CUETO) risk calculators are based.